Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep-Oct;34(5):411-414.
doi: 10.4103/lungindia.lungindia_116_17.

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer

Moushumi Suryavanshi  1 , Manoj Kumar Panigrahi  1 , Dushyant Kumar  1 , Haristuti Verma  1 , Mumtaz Saifi  1 , Bharti Dabas  1 , Ullas Batra  2 , Dinesh Doval  2 , Anurag Mehta  2
Affiliations

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer

Moushumi Suryavanshi et al. Lung India. 2017 Sep-Oct.

Abstract

Background: The frequency of ROS1 rearrangement in non-small cell lung cancers has been reported from 1.6% to 2.3%.

Materials and methods: We examined 105 lung adenocarcinoma patients for ROS1 rearrangement which were negative for EGFR and anaplastic lymphoma kinase. Clinical characteristics of ROS1 rearranged patients and their responses to crizotinib therapy were studied.

Results: Of the 105 patients, three cases were positive for ROS1 rearrangement by fluorescence in situ hybridization analysis. All of them showed heterogeneous pattern. All the 3 ROS1-positive patients were females in their forties and started on crizotinib. All of them responded to treatment. One of them developed resistance after 3 months. Another one showed marked systemic response but central nervous system lesions progressed. The third case is doing well till date with inactive lesions on positron emission tomography scan.

Conclusions: The frequency of ROS1 rearrangement is low in non-small cell lung carcinoma, but their diagnosis offers patients an opportunity to receive highly effective targeted therapies.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Response to treatment. Complete metabolic response to crizotinib from June 2015 to August 2015
Figure 2
Figure 2
Response to treatment. Complete metabolic response to crizotinib from April 2016 to August 2016
Figure 3
Figure 3
One locus harboring ROS1 as indicated by one orange/green fusion signal (nonrearranged), one orange signal, and one separate green signal indicating the translocation
See this image and copyright information in PMC

References

    1. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190–203. - PubMed
    1. Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol. 2013;24:2364–70. - PubMed
    1. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009;1795:37–52. - PubMed
    1. Charest A, Lane K, McMahon K, Park J, Preisinger E, Conroy H, et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21) Genes Chromosomes Cancer. 2003;37:58–71. - PubMed
    1. Gu TL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One. 2011;6:e15640. - PMC - PubMed